Senseonics is more than doubling revenue (118% YoY) with insider buying and 38.4% upside to the analyst target, but it burns cash at 122% of revenue, has missed EPS estimates four quarters in a row and reports earnings in 1 day.
Thesis pillars
- Revenue More Than Doubling→Stable
- Cash Burn Funding Risk→Stable
- Persistent Small Eps Misses↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 8, 2026, based on the 10-K filed Mar 2, 2026
Senseonics Holdings, Inc. (SENS) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $8.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Senseonics develops and commercializes Eversense, a long-term implantable continuous glucose monitoring system for people with diabetes, with sensors lasting up to 365 days versus 7-15 days for typical non-implantable CGMs. The company sells through distributors and fulfillment... Read more
Sell if holding. Engine safety override at $8.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 6.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: aggressive.
About Senseonics Holdings, Inc.
About Senseonics Holdings, Inc.
Senseonics markets Eversense E3 and Eversense 365, implantable continuous glucose monitors FDA-approved in September 2024 (365-day version) that measure glucose for up to a year versus 7 to 15 days for non-implantable CGMs. The company depends on this single product line for essentially all revenue, and as of January 1, 2026 resumed direct U.S. commercial responsibility from longtime partner Ascensia. Senseonics reported a $69.1 million net loss in 2025 against a $1.0 billion accumulated deficit.
Senseonics earns net revenue from sales of the Eversense sensor pack, smart transmitter pack, and, in some cases, procedure fees for insertion and removal, sold primarily through a network of distributors and strategic fulfillment partners who bill insurance payors, supplemented by a consignment model with healthcare professionals. Reimbursement coverage is central to adoption: Eversense became the first CGM reimbursed under Medicare Part B in November 2019, and the company has secured positive coverage decisions reaching approximately 300 million covered lives in the U.S., including UnitedHealthcare. The company outsources all manufacturing to third-party contract manufacturers, having no in-house production facilities or direct manufacturing personnel of its own. Looking ahead, Senseonics is developing its next-generation Gemini sensor (IDE-approved trial begun December 2025) and has partnered with Sequel Med Tech to integrate Eversense 365 into an automated insulin delivery system, with the first commercial patients starting on the combined system in January 2026.
Show full overview
The manufacturing dependency disclosed in Item 1A is structural, not incidental: Senseonics states it does not have any manufacturing facilities or direct manufacturing personnel and currently relies, and expects to continue relying, on third parties for the manufacture of Eversense for both commercial sale and future CGM product development. The 10-K frames loss of key suppliers or disruption to their facilities as a direct threat to gross margins and operating results, with no named backup manufacturer disclosed in this section. That concentration compounds the company's admitted single-product dependency — Senseonics states plainly that it is dependent on one product, Eversense — meaning a manufacturing disruption and a demand shortfall would hit the same, undiversified revenue stream simultaneously.
See also: Healthcare · Medical Devices
From Senseonics Holdings, Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Senseonics Holdings, Inc.
Latest news
- NEWS Sensirion to Showcase Sensor Innovations at electronica 2026 — fiscal.ai Nov 3, 2026 neutral
- NEWS Sensirion Announces Global Availability of SFM3304-D Single-Use Flow Sensor — fiscal.ai Oct 28, 2026 positive
- NEWS TD Cowen Reiterates Buy on Senseonics Holdings, Maintains $15 Price Target — benzinga Oct 27, 2026 neutral
- NEWS Senseonics Initiates First-in-Human Clinical Study for Freedom CGM System — fiscal.ai Oct 26, 2026 positive
- NEWS Senseonics Initiates First-In-Human Study Of Freedom — benzinga Oct 26, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-09T11:33:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductEversense10-K Item 1A: 'We are dependent on one product, Eversense. Our success depends on our ability to continue to develop, commercialize and gain market acceptance for our products.'
- HIGHSupplierthird-party manufacturers10-K Item 1A: 'We do not have any manufacturing facilities or direct manufacturing personnel. ... We currently rely, and expect to continue to rely, on third parties for the manufacture of Eversense'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -225.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $7.99. Score 6.3/10, moderate confidence.
Analyst target: $11.89 (+38.4% upside). Prior stop was $7.99. Stop-loss: $7.99.
Concentration risk — Product: Eversense; Concentration risk — Supplier: third-party manufacturers; Quality below floor (3.8 < 4.0).
Senseonics Holdings, Inc. trades at a P/E of N/A (forward -4.4). TrendMatrix value score: 7.0/10. Verdict: Sell.
13 analysts rate SENS, with a consensus score of 3.8/5. 6 analysts publish price targets averaging $14.
What does Senseonics Holdings, Inc. do?Senseonics develops and commercializes Eversense, a long-term implantable continuous glucose monitoring system for...
Senseonics develops and commercializes Eversense, a long-term implantable continuous glucose monitoring system for people with diabetes, with sensors lasting up to 365 days versus 7-15 days for typical non-implantable CGMs. The company sells through distributors and fulfillment partners who invoice insurance payors, and as of January 2026 resumed direct U.S. commercial responsibility after previously relying on Ascensia Diabetes Care as its exclusive worldwide distributor.